YUJIE ZHAO MD PHD NPI 1316153034

NPI Details

Yujie Zhao, MD PHD is a hematology and oncology internal medicine in Urbana, IL with 32 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Yujie Zhao, MD PHD NPI is 1316153034. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

509 W. UNIVERSITY AVE.
URBANA, IL
ZIP 61801-645
Phone: (217) 383-6636
Fax: (217) 383-3466

The NPI 1316153034 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg (HCPCS:Q5116)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Collection of blood sample from implanted device (HCPCS:36591)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Injection of drug or substance into vein (HCPCS:96374)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection, hydrocortisone sodium succinate, up to 100 mg (HCPCS:J1720)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)

The enumeration date for this NPI number is 5/16/2007 and was last updated on 10/20/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.